Agoniści receptorów aktywowanych proliferatorami peroksysomów w farmakoterapii. Obecne znaczenie i perspektywy zastosowania
Peroxisome proliferator-activated receptor agonists in pharmacotherapy: current status and prospects of usage

Summary/Abstract: Peroxisome proliferator-activated receptors (PPAR), present in three major isoforms (α, β / δ and γ), are nuclear transcription factors involved in lipid and glucose metabolism.Those receptors are targeted by fibrates (PPAR-α agonists) used in the hypertriglyceridemia and by thiazolidinediones (glitazones, affecting PPAR-γ), used as hypoglycemicagents in the treatment of type 2 diabetes. Furthermore, there is ongoing work on the new double receptor PPAR-α/γ agonists (glitazars) or compounds affecting both PPAR-γand free fatty acids receptors 1 (FFAR1). The ability to stimulate PPAR, resulted in anti inflammatory, anti-atherogenic and anti-proliferative properties, is also demonstrated by other compounds, such as statins, sartans or non-steroidal anti-inflammatory drugs. The revealed feature broadens their pharmaco dynamic description. To sum up, the agonistic effect on PPAR is an important element of the mechanism of action of many pharmacological agents, both drugs already applied in pharmaco therapy, and novel compounds that are currently in experimental studies and clinical trials.

• Details
• Contents